Pharmacy & Specialty Drug Management

A PBM arrangement can contain more than one compensation stream: an administrative fee, pharmacy network economics, specialty dispensing margin, manufacturer revenue, retained rebates and service fees. The employer’s job is not to assume every form of compensation is inappropriate. It is to understand precisely who earns what, from which transaction and under which contract definition.

A transparent decision begins with a written economic map. Ask for the contracted fee schedule, affiliates involved in dispensing or purchasing, every retained revenue category and a process for reconciling claims, invoices and credits. This moves pharmacy purchasing from a promise-based relationship to a governed one.

Spread pricing occurs when the plan is charged more than the dispensing pharmacy is paid and the difference is retained. The employer should be able to identify the applicable channels, calculation method and whether any spread is permitted. A pass-through label is meaningful only when the contract defines what must pass through and allows the employer to verify it.

Rebates may reduce net cost, but their visibility can obscure a higher gross cost or a less appropriate treatment choice. Evaluate net cost by therapy class alongside access, clinical evidence and member disruption. A large rebate is not automatically a better purchasing result.

Specialty medications require an integrated view of clinical management, fulfillment channel, site of care, manufacturer support and member experience. Review whether the plan can assess alternatives to PBM-owned specialty fulfillment and how urgent or limited-distribution medications are handled without creating avoidable friction.

For GLP-1s, establish coverage criteria, continuation rules, clinical support and a periodic utilization review before spending accelerates. For biosimilars, connect formulary placement with prescriber education, member communication and net-cost analysis. The objective is appropriate adoption, not an isolated utilization target.

Audit rights should specify usable claims and rebate data, a reasonable lookback period, independent reviewer access, vendor cooperation and remedies when results cannot be substantiated. Rights that arrive after the contract ends or exclude the economics at issue do not produce real accountability.

Guarantees need a baseline, a calculation method, exclusions, reporting cadence and remedy. Leadership should review each guarantee quarterly so variance triggers a decision while the arrangement can still be managed.

A quarterly review should show net cost per prescription, specialty share of spend, top therapy-class changes, rebate reconciliation, generic and biosimilar adoption, GLP-1 utilization, prior-authorization outcomes, member disruption and guarantee performance. Each measure should answer a decision question and have an accountable owner.

The meeting should end with documented decisions: which assumptions to test, which vendor commitments to validate and which employee-care issues require attention. This cadence turns pharmacy from a renewal exhibit into a managed health-plan capability.